Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.